{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:18:22Z","timestamp":1788290302223,"version":"build-2803163510"},"reference-count":26,"publisher":"American Chemical Society (ACS)","issue":"17","license":[{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_ccby_termsofuse.html"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome","doi-asserted-by":"publisher","award":["092340"],"award-info":[{"award-number":["092340"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome","doi-asserted-by":"publisher","award":["100476"],"award-info":[{"award-number":["100476"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Visceral leishmaniasis (VL) is a parasitic infection that results in approximately 26\u202f000\u201365\u202f000 deaths annually. The available treatments are hampered by issues such as toxicity, variable efficacy, and unsuitable dosing options. The need for new treatments is urgent and led to a collaboration between the Drugs for Neglected Diseases initiative (DNDi), GlaxoSmithKline (GSK), and the University of Dundee. An 8-hydroxynaphthyridine was identified as a start point, and an early compound demonstrated weak efficacy in a mouse model of VL but was hampered by glucuronidation. Efforts to address this led to the development of compounds with improved in vitro profiles, but these were poorly tolerated in vivo. Investigation of the mode of action (MoA) demonstrated that activity was driven by sequestration of divalent metal cations, a mechanism which was likely to drive the poor tolerability. This highlights the importance of investigating MoA and pharmacokinetics at an early stage for phenotypically active series.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.0c00705","type":"journal-article","created":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T13:05:13Z","timestamp":1594731913000},"page":"9523-9539","source":"Crossref","is-referenced-by-count":15,"title":["Identification\nand Optimization of a Series of 8-Hydroxy\nNaphthyridines with Potent\n                    <i>In Vitro<\/i>\n                    Antileishmanial\nActivity: Initial SAR and Assessment of\n                    <i>In Vivo<\/i>\n                    Activity"],"prefix":"10.1021","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0377-0281","authenticated-orcid":true,"given":"Michael G.","family":"Thomas","sequence":"first","affiliation":[{"name":"University of Dundee , , ,","place":["Dundee, United Kingdom, DD1 5EH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3171-3519","authenticated-orcid":true,"given":"Manu","family":"De Rycker","sequence":"additional","affiliation":[{"name":"University of Dundee , , ,","place":["Dundee, United Kingdom, DD1 5EH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Wall","sequence":"additional","affiliation":[{"name":"University of Dundee , , ,","place":["Dundee, United Kingdom, DD1 5EH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Spinks","sequence":"additional","affiliation":[{"name":"University of Dundee , , ,","place":["Dundee, United Kingdom, DD1 5EH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Epemolu","sequence":"additional","affiliation":[{"name":"University of Dundee , , ,","place":["Dundee, United Kingdom, DD1 5EH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujatha","family":"Manthri","sequence":"additional","affiliation":[{"name":"University of Dundee , , ,","place":["Dundee, United Kingdom, DD1 5EH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Norval","sequence":"additional","affiliation":[{"name":"University of Dundee , , ,","place":["Dundee, United Kingdom, DD1 5EH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Osuna-Cabello","sequence":"additional","affiliation":[{"name":"University of Dundee , , ,","place":["Dundee, United Kingdom, DD1 5EH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Patterson","sequence":"additional","affiliation":[{"name":"University of Dundee , , ,","place":["Dundee, United Kingdom, DD1 5EH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Riley","sequence":"additional","affiliation":[{"name":"University of Dundee , , ,","place":["Dundee, United Kingdom, DD1 5EH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick R. C.","family":"Simeons","sequence":"additional","affiliation":[{"name":"University of Dundee , , ,","place":["Dundee, United Kingdom, DD1 5EH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laste","family":"Stojanovski","sequence":"additional","affiliation":[{"name":"University of Dundee , , ,","place":["Dundee, United Kingdom, DD1 5EH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Thomas","sequence":"additional","affiliation":[{"name":"University of Dundee , , ,","place":["Dundee, United Kingdom, DD1 5EH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Thompson","sequence":"additional","affiliation":[{"name":"University of Dundee , , ,","place":["Dundee, United Kingdom, DD1 5EH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Naylor","sequence":"additional","affiliation":[{"name":"University of Dundee , , ,","place":["Dundee, United Kingdom, DD1 5EH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Fiandor","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline , , ,","place":["Tres Cantos, Spain, 28760"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0397-245X","authenticated-orcid":true,"given":"Paul G.","family":"Wyatt","sequence":"additional","affiliation":[{"name":"University of Dundee , , ,","place":["Dundee, United Kingdom, DD1 5EH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2442-0021","authenticated-orcid":true,"given":"Maria","family":"Marco","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline , , ,","place":["Tres Cantos, Spain, 28760"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8810-5605","authenticated-orcid":true,"given":"Susan","family":"Wyllie","sequence":"additional","affiliation":[{"name":"University of Dundee , , ,","place":["Dundee, United Kingdom, DD1 5EH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8536-0130","authenticated-orcid":true,"given":"Kevin D.","family":"Read","sequence":"additional","affiliation":[{"name":"University of Dundee , , ,","place":["Dundee, United Kingdom, DD1 5EH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7407-7404","authenticated-orcid":true,"given":"Timothy J.","family":"Miles","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline , , ,","place":["Tres Cantos, Spain, 28760"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5238-1314","authenticated-orcid":true,"given":"Ian H.","family":"Gilbert","sequence":"additional","affiliation":[{"name":"University of Dundee , , ,","place":["Dundee, United Kingdom, DD1 5EH"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2020,7,14]]},"reference":[{"key":"2026090115000969000_cit1","volume-title":"World\nHealth Organization (WHO) List of Neglected Tropical Diseases","year":"2018"},{"key":"2026090115000969000_cit2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nrmicro.2016.193","article-title":"Anti-trypanosomatid\nDrug Discovery:\nan Ongoing Challenge and a Continuing Need","volume":"15","author":"Field","year":"2017","journal-title":"Nat. Rev. Microbiol."},{"key":"2026090115000969000_cit3","volume-title":"World\nHealth Organization (WHO) Leishmaniasis Fact Sheet","year":"2019"},{"key":"2026090115000969000_cit4","first-page":"733","article-title":"Miltefosine in the\ntreatment of leishmaniasis: Clinical\nEvidence for Informed Clinical Risk Management","volume":"3","author":"Sundar","year":"2007","journal-title":"Ther. Clin. Risk Manage."},{"key":"2026090115000969000_cit5","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1056\/NEJMoa066536","article-title":"Injectable\nParomomycin for Visceral Leishmaniasis in India","volume":"356","author":"Sundar","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"2026090115000969000_cit6","unstructured":"Drugs for Neglected\nDiseases initiative\n(DND i) Portfolio. https:\/\/www.dndi.org\/diseases-projects\/leishmaniasis\/leish-portfolio\/ (accessed April 23, 2020)."},{"key":"2026090115000969000_cit7a","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41586-018-0356-z","article-title":"Cyclin-Dependent\nKinase 12 is a Drug\nTarget for Visceral Leishmaniasis","volume":"560","author":"Wyllie","year":"2018","journal-title":"Nature"},{"key":"2026090115000969000_cit7b","doi-asserted-by":"publisher","first-page":"9318","DOI":"10.1073\/pnas.1820175116","article-title":"Preclinical Candidate for the Treatment\nof Visceral Leishmaniasis that Acts Through Proteasome Inhibition","volume":"116","author":"Wyllie","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2026090115000969000_cit7c","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/nature19339","article-title":"Proteasome Inhibition for Treatment\nof Leishmaniasis, Chagas Disease and Sleeping Sickness","volume":"537","author":"Khare","year":"2016","journal-title":"Nature"},{"key":"2026090115000969000_cit8","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1128\/AAC.02398-12","article-title":"Comparison\nof a High-Throughput High Content Intracellular Leishmania donovani Assay with an Axenic Amastigote Assay","volume":"57","author":"De Rycker","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090115000969000_cit9","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1017\/S003118201300142X","article-title":"Screening Strategies to Identify New Chemical Diversity\nfor Drug Development to Treat Kinetoplastid Infections","volume":"141","author":"Don","year":"2014","journal-title":"Parasitology"},{"key":"2026090115000969000_cit10","doi-asserted-by":"publisher","DOI":"10.1038\/srep08771","article-title":"New Compound Sets Identified from\nHigh Throughput Phenotypic Screening against Three Kinetoplastid Parasites:\nan Open Resource","volume":"5","author":"Pen\u0303a","year":"2015","journal-title":"Sci. Rep."},{"key":"2026090115000969000_cit11","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.drudis.2011.06.001","article-title":"Getting Physical\nin Drug Discovery II: the Impact of Chromatographic Hydrophobicity\nMeasurements and Aromaticity","volume":"16","author":"Young","year":"2011","journal-title":"Drug Discovery\nToday"},{"key":"2026090115000969000_cit12","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1021\/acs.jmedchem.8b01218","article-title":"Identification of GSK3186899\/DDD853651\nas a Preclinical Development Candidate for the Treatment of Visceral\nLeishmaniasis","volume":"63","author":"Thomas","year":"2019","journal-title":"J. Med. Chem."},{"key":"2026090115000969000_cit13","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.bmcl.2006.11.080","article-title":"A Potent\nand Orally Active HIV-1 Integrase Inhibitor","volume":"17","author":"Egbertson","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026090115000969000_cit14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2174\/1389200003339171","article-title":"UPD-Glucuronosyltransferases","volume":"1","author":"King","year":"2000","journal-title":"Curr. Drug Metab."},{"key":"2026090115000969000_cit15","doi-asserted-by":"publisher","first-page":"10136","DOI":"10.1021\/jm301252n","article-title":"Novel Acidic\n11\u03b2-Hydroxysteroid Dehydrogenase Type 1 (11\u03b2-HSD1) Inhibitor\nwith Reduced Acyl Glucuronide Liability: The Discovery of 4-[4-(2-Adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic Acid (AZD8329)","volume":"55","author":"Scott","year":"2012","journal-title":"J. Med. Chem."},{"key":"2026090115000969000_cit16","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.2165\/00003495-200969080-00007","article-title":"Raltegravir","volume":"69","author":"Croxtall","year":"2009","journal-title":"Drugs"},{"key":"2026090115000969000_cit17a","doi-asserted-by":"publisher","first-page":"11233","DOI":"10.1073\/pnas.0402357101","article-title":"A Naphthyridine\nCarboxamide Provides Evidence for Discordant Resistance Between Mechanistically\nIdentical Inhibitors of HIV-1 Integrase","volume":"101","author":"Hazuda","year":"2004","journal-title":"Proc.\nNatl. Acad. Sci. U.S.A."},{"key":"2026090115000969000_cit17b","unstructured":"(b)\n          \n            \n              Little, S.; Drusano, G.; Schooley, R. In  Antiviral Effect of\nL-000870810, a Novel HIV-1 Integrase Inhibitor, in HIV-1 Infected\nPatients, 12th Conference on Retroviruses and Opportunistic\nInfections, Boston, MA, Abstract 161, Feb 22\u201325, 2005."},{"key":"2026090115000969000_cit18","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nrd3845","article-title":"Reducing Safety-Related\nDrug Attrition: The Use of in Vitro Pharmacological Profiling","volume":"11","author":"Bowes","year":"2012","journal-title":"Nat. Rev. Drug Discovery"},{"key":"2026090115000969000_cit19","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00235-18","article-title":"Antitrypanosomal 8-Hydroxy-Naphthyridines\nare Chelators of Divalent Transition Metals","volume":"62","author":"Wall","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090115000969000_cit20","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1016\/j.bmcl.2009.01.090","article-title":"The Use of Oxadiazole\nand Triazole Substituted Naphthyridines as HIV-1 Integrase Inhibitors.\nPart 1: Establishing the Pharmacophore","volume":"19","author":"Johns","year":"2009","journal-title":"Bioorg.\nMed. Chem. Lett."},{"key":"2026090115000969000_cit21","unstructured":"Crescenzi, B.; Gardelli, C.; Muraglia, E.; Nizi, E.; Orvieto, F.; Pace, P.; Pescatore, G.; Petrocchi, A.; Poma, M.; Rowley, M.; Scarpelli, R.; Summa, V.\n          N-Substituted Hydroxypyrimidinone\nCarboxamide Inhibitors\nof HIV Integrase. WO2003035077, 2003."},{"key":"2026090115000969000_cit22","doi-asserted-by":"publisher","first-page":"9492","DOI":"10.1021\/jm300667v","article-title":"Repositioning\nHIV-1 Integrase Inhibitors for Cancer Therapeutics: 1,6-Naphthyridine-7-carboxamide\nas a Promising Scaffold with Drug-like Properties","volume":"55","author":"Zeng","year":"2012","journal-title":"J. Med. Chem."},{"key":"2026090115000969000_cit23","doi-asserted-by":"publisher","first-page":"7284","DOI":"10.1021\/acs.jmedchem.7b00463","article-title":"Discovery and Optimization\nof 5-Amino1,2,3-triazole-4-carboxamide Series against Trypanosoma\ncruzi","volume":"60","author":"Brand","year":"2017","journal-title":"J. Med. Chem."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.0c00705","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/63\/17\/9523\/67503967\/acs.jmedchem.0c00705.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/63\/17\/9523\/67503967\/acs.jmedchem.0c00705.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:00:16Z","timestamp":1788289216000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/63\/17\/9523\/1341264\/Identification-and-Optimization-of-a-Series-of-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,14]]},"references-count":26,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2020,7,14]]},"published-print":{"date-parts":[[2020,9,10]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00705","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,14]]}}}